532523:BOM
Biocon Ltd
Rs 348,10
arrow_downward
-0,97%(-3,40) 1 HR
16 Okt, 15.14.50 GMT+5.30 · INR
search
Semua simbol
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk 532523...
Pembukaan
Rs 352,95
Tinggi
Rs 352,95
Rendah
Rs 348,10
Kapitalisasi pasar
566,83Â M
Volume rata-rata
692,61Â rb
Volume
668,24Â rb
Dividen
0,14%
Dividen per kuartal
Rs 0,12
Tanggal tanpa dividen
3 Jul 2026
Rasio P/E
103,06
Harga tinggi dalam 52 minggu terakhir
Rs 447,00
Harga rendah dalam 52 minggu terakhir
Rs 337,95
EPS
Rs 3,38
Saham beredar
600,00Â jt
Jumlah karyawan
16Â rb
Pembukaan
Rs 352,95
Tinggi
Rs 352,95
Rendah
Rs 348,10
Kapitalisasi pasar
566,83Â M
Volume rata-rata
692,61Â rb
Volume
668,24Â rb
Dividen
0,14%
Dividen per kuartal
Rs 0,12
Tanggal tanpa dividen
3 Jul 2026
Rasio P/E
103,06
Harga tinggi dalam 52 minggu terakhir
Rs 447,00
Harga rendah dalam 52 minggu terakhir
Rs 337,95
EPS
Rs 3,38
Saham beredar
600,00Â jt
Jumlah karyawan
16Â rb
Artikel berita
Dari sumber web dan partner berita
Dalal Street Investment Journal
·
2 hari yang lalu
Biocon settles Genentech disputes, secures 2027 EU and 2028 US launch window for Pebrilzo
HDFC Sky
·
2 hari yang lalu
Biocon Secures Pebrilzo Launch Dates; Shares Fall 0.94%
TipRanks
·
2 hari yang lalu
Biocon Secures Global Deal with Genentech to Launch Pebrilzo Biosimilar
Profil
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Tentang Biocon Ltd
CEOShreehas P Tambe
Karyawan16,4Â rb
Didirikan29 Nov 1978
Kantor PusatBengaluru, Karnataka, India
Sektor-
Situsbiocon.com